Filtered By:
Condition: Diabetes
Education: Teaching Hospitals
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 23 results found since Jan 2013.
Abstract 340: Thirty-day Repeat Hospitalizations for Patients Treated with Prasugrel Compared to Ticagrelor following Acute Coronary Syndrome: Findings from a Large Hospital Charge Master Database Session Title: Poster Session III
Conclusion: Rehosp for MI, revasc or bleeding was non-inferior for pras compared to ticag at 30 days post discharge. Pts treated with pras had lower 30 day rehosp rates, particularly related to readmission for MI, compared with ticag. Although limited by selection bias, these results support the clinical utility of pras, regardless of cohort, to limit 30 day rehosp for pts undergoing PCI for ACS.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Vetrovec, G. W., Larmore, C., Molife, C., DeKoven, M., Karkare, S., Zhu, Y. E., Frech-Tamas, F., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Effron, M. B. Tags: Session Title: Poster Session III Source Type: research
Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention
CONCLUSION: The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.PMID:35537720 | DOI:10.15537/smj.2022.43.5.20220018
Source: Atherosclerosis - May 10, 2022 Category: Cardiology Authors: Seyed Mohammad H Adel Fateme Jorfi Hoda Mombeini Homeira Rashidi Saad Fazeli Source Type: research
